83-5960-90　PD-1, Nivolumab Biosimilar 5mg　587282

特徴

• What is Nivolumab biosimilar research grade? Nivolumab is a humanized IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1).
• This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation S228P for additional stability and reduced variability.
• Nivolumab Biosimilar uses the same protein sequences as the therapeutic antibody nivolumab.
• PD-L1 and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD-1 (CD279, programmed cell death protein 1).
• Nivolumab blocks PD-1 inhibitory signalling to T-cells.
• It has a long duration of action as it is administered every 2-4 weeks.
• Patients should be counselled regarding the risk of immune-mediated adverse effects, infusion-related adverse effects, complications of allogenic hematopoietic stem cell transplants, embryo-fetal toxicity.
• The ligands PD-L1 and PD-L2 bind to the PD-1 receptor on T-cells, inhibiting the action of these cells.
• Tumor cells express PD-L1 and PD-L2.
• Nivolumab binds to PD-1, preventing PD-L1 and PD-L2 from inhibiting the action of T-cells, restoring a patient's tumor-specific T-cell response.
• Applications:Suitable for use in ELISA, Neutralization, Functional Assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by nivolumab.
• Other applications not tested.
• Recommended Dilution:Optimal dilutions to be determined by the researcher.
• Storage and Stability:May be stored at 4℃ for short-term only.
• Aliquot to avoid repeated freezing and thawing.
• Store at -20℃.
• Aliquots are stable for 12 months after receipt.
• For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.